A phase II study of gemcitabine by fixed-dose rate infusion, cisplatin, and celecoxib in metastatic pancreatic cancer.

被引：0
|
作者：
Kobrossy, B
El-Rayes, BF
Shields, AF
Vaishampayan, U
Heilbrun, L
Zalupski, MM
Philip, PA
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4120
引用
收藏
页码：343S / 343S
页数：1
相关论文
共 50 条
  • [31] Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Morizane, Chigusa
    Okusaka, Takuji
    Ueno, Hideki
    Kondo, Shunsuke
    Ikeda, Masafumi
    Furuse, Junji
    Shinichi, Ohkawa
    Nakachi, Kohei
    Mitsunaga, Shuichi
    Kojima, Yasushi
    Suzuki, Eiichiro
    Ueno, Makoto
    Yamaguchi, Tomohiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 957 - 964
  • [32] Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Chigusa Morizane
    Takuji Okusaka
    Hideki Ueno
    Shunsuke Kondo
    Masafumi Ikeda
    Junji Furuse
    Ohkawa Shinichi
    Kohei Nakachi
    Shuichi Mitsunaga
    Yasushi Kojima
    Eiichiro Suzuki
    Makoto Ueno
    Tomohiro Yamaguchi
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 957 - 964
  • [33] Phase II study of a fixed dose-rate infusion of gemcitabine associated to cisplatin and UFT in advanced carcinoma of the pancreas, an ONCOPAZ study.
    Espinosa, E
    Sáenz, JG
    Rodríguez-Jaráiz, A
    Castañon, C
    Cruz, M
    Fonseca, E
    Feliu, J
    Lomas, M
    Barón, MG
    Jara, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 338S - 338S
  • [34] Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer
    Brodowicz, T
    Wolfram, RM
    Köstler, WJ
    Tomek, S
    Vaclavik, I
    Steger, GG
    Teleky, B
    Függer, R
    Jakesz, R
    Zielinski, CC
    ANTI-CANCER DRUGS, 2000, 11 (08) : 623 - 628
  • [35] A phase II study of gemcitabine with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
    Uwagawa, T.
    Misawa, T.
    Gocho, T.
    Iida, T.
    Wakiyama, S.
    Hirohara, S.
    Sakamoto, T.
    Yanaga, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials
    Jiqing Xie
    Jing Yuan
    Laichun Lu
    Diagnostic Pathology, 9
  • [37] Phase II study of gemcitabine and Flutamide in advanced pancreatic cancer.
    Mayer, A
    Shaw, J
    D'Ath, S
    Price, P
    Blesing, C
    Corrie, P
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [38] Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials
    Xie, Jiqing
    Yuan, Jing
    Lu, Laichun
    DIAGNOSTIC PATHOLOGY, 2014, 9 : 214
  • [39] Fixed dose-rate gemcitabine (GEM) infusion in advanced pancreatic (PDAC) and biliary tree (BTC) carcinoma: A phase II study
    Gelibter, A
    Di Cosimo, S
    Ruggeri, EM
    Carlini, P
    Bria, E
    Malaguti, P
    Pellicciotta, M
    Terzoli, E
    Cognetti, F
    Milella, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 358S - 358S
  • [40] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Najima, M.
    Hirokawa, S.
    Nakachi, K.
    Ogura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
12345